A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
Epistemonikos ID: c5fe09b182e87dcf90d30ac4d65ceceb1dedf6d2
First added on: May 14, 2024